Connect with us

Press Release

CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China

Published

on

SHENZHEN, CHINA China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.

The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.

More information about Desidustat Tablets and Renal Anaemia

As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.

There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.

Desidustat Tablets have been approved for marketing in India.

CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.

The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference

1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6

2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015

3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)

4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

ForumPay Expands Payment Infrastructure with New Card and Bank Transfer Acceptance Solution

Published

on

Milton, Georgia, August 11th, 2026, Chainwire

Businesses are increasingly looking for ways to offer more payment options without adding operational complexity. ForumPay, a crypto payment infrastructure company, enables merchants to accept crypto payments across online, in-store, and in-app channels, with instant conversion and next-day settlement.

ForumPay has recently announced a new payment flow that it says could meaningfully alter how payments are processed. Customers can now initiate purchases using any Visa or Mastercard and bank transfers in selected markets, with funds routed automatically through ForumPay’s infrastructure. Merchants can now offer card and bank payments without registering as a card acceptance businesses, sidestepping chargeback liability and PCI-DSS compliance costs while still receiving precisely the amount invoiced. 

This latest ForumPay release represents one of the more ambitious developments yet to bridge the gap between traditional payment rails and crypto infrastructure. 

Built for Modern Payment Acceptance

Businesses increasingly want to offer customers greater flexibility at checkout, but additional payment methods tend to bring additional operational and cost burdens. Card acceptance, in particular, can introduce chargeback exposure, compliance requirements, fraud management responsibilities, and more complex settlement processes, challenges that only grow more acute for organizations operating across multiple markets.

ForumPay’s innovative new payment flow is designed to solve these issues. Customers can initiate payments using any Visa, Mastercard, or bank transfer in selected markets, with those funds automatically used to purchase crypto and processed through ForumPay’s existing crypto payment infrastructure, with all of the inherent features and benefits, and converted and settled as per the preferences a merchant has already established on their account. Merchants will receive exactly the amount invoiced. For example, if a customer is billed $100, then $100 is what arrives in the merchant’s preferred bank account.

Critically, ForumPay will pass the additional card and bank transfer costs directly to the payer, meaning merchants pay only their usual crypto acceptance fees that would apply to any transaction processed through the platform. The approach allows businesses to expand the choice of available payment methods at checkout without taking on the compliance architecture, risks and costs that card acceptance would ordinarily require.

More Payment Options, the Same Operational Footprint 

Businesses increasingly want to offer customers greater flexibility at checkout, but incorporating additional payment methods tend to bring with it additional operational burdens. Card acceptance, in particular, can introduce chargeback exposure, compliance requirements, fraud management responsibilities, and more complex settlement processes, challenges that only grow more acute for organizations operating across multiple markets. 

ForumPay’s new payment flow is being designed to address this friction. Customers will be able to initiate payments using any Visa, Mastercard, or bank transfer in selected markets. Those funds are then automatically used to purchase digital assets and processed through ForumPay’s existing infrastructure, allowing merchants to continue receiving funds according to their established settlement preferences without having to overhaul their operations to accommodate the new options in the process. The approach, ForumPay says, allows businesses to expand what they can offer at checkout without taking on the compliance architecture that card acceptance would ordinarily require.

About ForumPay

ForumPay is a complete cryptocurrency-to-fiat payment technology firm; its core processing technology helps businesses attract new customers, optimize customers’ ability to spend, and increase revenue. ForumPay’s wallet-agnostic solution enables crypto consumers to spend their preferred cryptocurrency, from any wallet for everyday goods and services to luxury goods, automobiles, real estate, and private jets. ForumPay eliminates merchant exposure or risk by processing transactions with instant crypto-to-cash conversion. ForumPay merchants receive payments in the currency of their choice directly into their bank account. The transactional experience is similar to accepting other popular payment methods, including cash, credit cards, and bank transfers, but simpler, faster, and more secure.

Contact

Director Global Account Management
Paul Wordsworth
ForumPay
paul@forumpay.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Counter-UAS Market Set to Triple by 2030 as Defense Companies Position for Growth

Published

on

Naples, FL, USA, August 11th, 2026, FinanceWire

Drones have become a growing security problem, and the market to stop them is expanding just as quickly. MarketsandMarkets estimates the global counter-unmanned aircraft systems market will grow from $6.64 billion in 2025 to $20.31 billion by 2030, representing a 25.1 percent compound annual growth rate. Within that forecast, AI-powered counter-UAS is the fastest-growing technology layer, projected to expand from $0.9 billion in 2025 to $6.2 billion by 2030. As governments and critical infrastructure operators look for ways to detect, track, and defeat increasingly sophisticated drone threats, defense companies are racing to build the next generation of counter-UAS technology. Several public companies are already staking positions in counter-UAS, approaching the opportunity from different angles.

Change Agents Corp. (Nasdaq: CHGA) has joined the Institute for Defense and Government Advancement, or IDGA, and will take part in the organization’s Counter UAS Summit. Now in its eighth year, the summit runs August 25 to 26 at the MGM National Harbor in Maryland under the chairmanship of retired General Glen VanHerck, former commander of North American Aerospace Defense Command and U.S. Northern Command. IDGA expects more than 500 senior decision-makers, acquisition leaders, and program managers from the Army, Navy, Air Force, Marines, Customs and Border Protection, and law enforcement, placing Change Agents in direct contact with the buyers and technology developers shaping counter-drone procurement.

The summit role builds on the company’s August 4 launch of Autonomous Air Defense LLC, a wholly owned subsidiary formed to identify, evaluate, acquire, and develop autonomous air defense and counter-UAS technologies. That announcement also brought retired Major General Malcolm Frost onto the advisory boards of both Change Agents and the new subsidiary. Frost served 31 years in the U.S. Army, retiring as a two-star general after commanding the 2nd Stryker Brigade Combat Team of the 25th Infantry Division and serving as Deputy Commanding General of the 82nd Airborne Division. He is a West Point and Army War College graduate who deployed to Bosnia, Iraq, and Afghanistan, and he advises public and private companies across the defense and technology sectors.

Change Agents built its business in agentic AI software, pairing an AI search optimization platform called Beacon with an autonomous content creation platform called Catch-Up, both sold on a subscription model. Management frames the counter-drone move as an outgrowth of that work rather than a break from it. Director Michael Mathews called the formation of Autonomous Air Defense LLC “a natural extension of the company’s broader artificial intelligence strategy” and tied the IDGA engagement to positioning the company to “capitalize on the significant long-term opportunities within the global counter-UAS market. ” Frost, in joining, pointed to the convergence of artificial intelligence, autonomous systems, and next-generation counter-drone technology as one of the most important developments in modern defense.

That convergence is the opening Change Agents intends to pursue, and the sequence so far has been deliberate. In roughly a week the company has stood up a dedicated subsidiary, added a decorated defense advisor, and secured a place at the sector’s principal U.S. gathering. The company has said Autonomous Air Defense is evaluating multiple acquisition and partnership opportunities involving AI-enabled counter-drone technologies serving defense, homeland security, and critical infrastructure customers, and that it expects to provide further updates as developments occur. 

Change Agents is entering a field already populated by well-funded public companies attacking the drone problem from different angles.

Ondas Inc. (Nasdaq: ONDS) is the closest analog to what Change Agents describes. Its Iron Drone Raider is an autonomous net-based interceptor built to neutralize hostile drones without jamming, paired with its Sentrycs platform for cyber and radio-frequency detection and identification, together mirroring the detect, identify, track, and intercept sequence Change Agents has said it wants to reach. Ondas posted first-quarter 2026 revenue of $50.1 million against a pro forma backlog of $457 million and in July raised its full-year 2026 revenue target to at least $525 million. In February its Airobotics subsidiary secured a multi-million-dollar order from a European customer in a NATO country following an Iron Drone Raider deployment at a major international airport, one of the few operational uses of an interceptor drone in a live civil-aviation setting.

AeroVironment (Nasdaq: AVAV) approaches the market as an established contractor. Its acquisition of BlueHalo, valued at roughly $4.1 billion and completed in May 2025, added directed energy, electronic warfare, and counter-UAS capabilities to a portfolio already known for the Switchblade family of loitering munitions. BlueHalo had delivered its 1,000th Titan radio-frequency counter-UAS system before the deal closed and was the first to operationally field a laser weapon system with LOCUST. The combination turned a former drone specialist into a diversified defense technology platform spanning radio-frequency, directed energy, and kinetic defeat, and it marks the scaled version of the category Change Agents is entering.

Kratos Defense & Security Solutions (Nasdaq: KTOS) anchors the autonomous systems end of the field. Best known for the jet-powered XQ-58A Valkyrie, Kratos reported second-quarter 2026 revenue of $458.8 million, up 30.5 percent year over year and 19.1 percent organically, and raised full-year 2026 guidance to a range of $1.75 billion to $1.81 billion. Total backlog stood at $2.084 billion against a bid pipeline of $15.0 billion, a measure of how much defense money is now moving through unmanned and autonomous programs, and of the budgets, Change Agents is positioning to reach.

Ondas, AeroVironment, and Kratos map the opportunity from interceptor specialist to diversified prime, and they mark out the market Change Agents Corp. (Nasdaq: CHGA) has chosen to enter. What CHGA has established is a subsidiary, an advisor with two-star command experience, and access to the procurement community setting counter-drone requirements. What remains prospective is the technology itself, and the company has said it expects to report further developments as it works through the acquisition and partnership opportunities in front of it.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Change Agents Corp to assist in the production and distribution of content related to CHGA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Contact

Mark McKelvie
RazorPitch
mark@razorpitch.com
585-301-7700

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

HoneyBook Included in CNBC’s 2026 List of the World’s Top Fintech Companies

Published

on

San Francisco, California, USA, August 11th, 2026, FinanceWire

The ranking validates HoneyBook’s growing reputation as an innovator accelerating the digital transformation of independent businesses globally 

HoneyBook, the leading AI-native client relationship platform for small business owners, has been recognized as one of the world’s most significant financial technology firms in CNBC’s 2026 list of the World’s Top Fintech Companies. Its inclusion in the prestigious global list within the Enterprise Fintech category underscores the impact that HoneyBook’s software has had in helping individual business owners to cultivate strong customer relationships.  

Produced in partnership with Statista, CNBC’s list is a recognized annual ranking that serves to highlight the world’s most innovative and forward-thinking financial software firms. As part of its assessment process, CNBC evaluates thousands of eligible firms, ranging from startups to established enterprises, based on key performance indicators such as revenue and user growth, transaction volume, business impact and technological innovation. HoneyBook’s debut on this year’s list reflects growing recognition of its platform.

HoneyBook is noted for accelerating automation in the customer relationship management software niche, helping business and freelancers to better manage their day-to-day dealings with clients. Its platform frees users from spending hours on critical business tasks such as capturing and verifying inquiries, drafting proposals, obtaining signatures on contracts, sharing files with customers and processing transactions. With HoneyBook, business owners can manage their administrative and financial operations in a unified platform, making use of autonomous AI agents to perform work they once spent hours on. By linking client communications with financial operations, HoneyBook helps business professionals to work more efficiently and get paid promptly. 

CNBC’s recognition of HoneyBook follows the rapid expansion of its client relationship platform into new verticals. Last month, HoneyBook launched a dedicated version of its CRM platform for professional photographers, featuring specialized tools for client bookings, creating schedules, managing their galleries and collaborating with clients on projects. With HoneyBook, photographers get more time to focus on their clients and their work instead of worrying about the administrative side of their business. 

“I’m extremely proud that our endeavors to enhance and simplify client relationships have led to HoneyBook being recognized by CNBC as one of the world’s best fintech companies,” said Oz Alon, co-founder and Chief Executive Officer of HoneyBook. “By enabling business owners to nurture relationships with clients in the same place as they manage their finances, HoneyBook significantly reduces the complexity they face when using multiple fragmented tools. CNBC’s recognition validates our ability to empower independent entrepreneurs with innovative tools that streamline the day-to-day aspects of business management.” 

About HoneyBook

HoneyBook is the leading AI-powered customer relationship management (CRM) platform for independent business owners, making it easy to sell and deliver their services online. Offering powerful tools for communication, contracts, invoicing, payments and more, the platform puts independent professionals in control of their process and client experience. HoneyBook is trusted by over 100,000 service-based businesses in the United States, Australia, Canada, and the United Kingdom that have booked more than $10 billion in business on the platform. The company has offices in San Francisco and Tel Aviv, with remote staff worldwide. Learn more at HoneyBook.com.

Contact

Dan Edelstein
InboundJunction
pr@inboundjunction.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST